Latest Hotspot

Medicenna unveils positive survival results from the Phase 2b trial of Bizaxofusp for recurrent Glioblastoma at the 28th annual NeuroOncology Society meeting

24 November 2023
3 min read

Medicenna Therapeutics Corp., an immunotherapy business currently in the clinical stage, concentrating on the advancement of Superkines, has declared a poster exhibition and a spoken overview featuring extended follow-up outcomes from the Phase 2b medical examination of bizaxofusp, the company's ground-breaking IL-4R focused medication for the cure of recurrent glioblastoma. These will be showcased by Dr. Steven Brem, M.D., at the Society for Neuro-Oncology 2023 Annual Gathering, scheduled from November 15 to 19, 2023, in Vancouver, Canada. The company specializes in the first-to-market segments of healthcare.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

"Bizaxofusp presents an innovative technique by showing a dose-responsive effect on the IL-4 receptor, a cytokine known for its immune-suppressive abilities. Additionally, employing bizaxofusp either alone or in combination could possibly 'turn the tables' on glioblastoma, transforming it from an immunologically 'inert' mass into a receptive one, by utilizing convection enhanced delivery to 'take the battle to the tumor'. 

This information gives fresh optimism to glioblastoma patients who have sparse selections for treatment upon recurrence," stated Dr. Steven Brem. "The doubling of survival benefit in incurable rGBM resulting from a solitary bizaxofusp treatment, even after an additional 22 months of follow-up, strengthens the reliability of the initial primary analysis," expressed Fahar Merchant, Ph.D.

Medicenna’s President CEO. Dr. Merchant continued, “Working closely with regulatory bodies, our initiatives have secured us a groundbreaking Phase 3 trial design in rGBM using an external control arm and we are actively in search of collaborations to further advance the bizaxofusp registration study. 

Following our Phase 2b outcome announcement in the journal Neuro-Oncology® earlier this year, we are excited to share our updated 4-year follow-up findings at SNO 2023 with the medical and research communities.” Medicenna has received approval from the U.S. FDA on the trial design for the Phase 3 LIGHT™ study and is running after potential collaborations to commence the LIGHT trial, and should it be approved, to roll out bizaxofusp across pivotal global markets.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of November 23, 2023, there are 45 investigational drugs for the IL-4Rα target, including 72 indications, 68 R&D institutions involved, with related clinical trials reaching 410, and as many as 5279 patents.

Bizaxofusp is Medicenna’s IL-4 Empowered Superkine that has been studied in 5 clinical trials in over 130 patients, including a Phase 2b trial in patients with recurrent glioblastoma, the most common and uniformly fatal form of brain cancer. Bizaxofusp has been granted FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.

图形用户界面, 文本, 应用程序

描述已自动生成

EXS-21546: A Quick Look at Its R&D Progress and Clinical Results from the 2023 AACR
EXS-21546: A Quick Look at Its R&D Progress and Clinical Results from the 2023 AACR
24 November 2023
On 14 Apr 2023, data from first-in-human study of EXS21546, an A2A receptor antagonist, was reported at the AACR Congress.
Read →
EBGLYSS® (lebrikizumab) received European Commission approval for treating moderate-to-severe atopic dermatitis
Latest Hotspot
3 min read
EBGLYSS® (lebrikizumab) received European Commission approval for treating moderate-to-severe atopic dermatitis
24 November 2023
EBGLYSS® (lebrikizumab), developed by Almirall, has been given the green light by the European Commission for the treatment of moderate-to-severe atopic dermatitis.
Read →
What are CDKs inhibitors and how do you quickly get the latest development progress?
What are CDKs inhibitors and how do you quickly get the latest development progress?
24 November 2023
The development of inhibitors around the entire CDK family has become an important branch of drug development in the field of oncology in recent years.
Read →
US approved Truqap (capivasertib) and Faslodex combo for advanced HR-positive breast cancer
Latest Hotspot
3 min read
US approved Truqap (capivasertib) and Faslodex combo for advanced HR-positive breast cancer
24 November 2023
US approval granted for combination of Truqap (capivasertib) and Faslodex for treating advanced HR-positive breast cancer patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.